Thursday, April 17, 2014

NeoGenomics Launches Cancer Profiles neotype based NGS 23

Tags

NeoGenomics Launches Cancer Profiles neotype based NGS 23 -

NeoGenomics, Inc. (NASDAQ: NEO) , a provider cancer genetics focused leadership and service molecular tests, announced today that it has launched 23 new and innovative ™ cancer Profiles neotype based on next-generation sequencing (NGS). These new advanced cancer profiling tools provide oncologists and pathologists more targeted and comprehensive ability to tailor cancer screening needs of each patient that has never been available before.

next generation sequencing is an advanced molecular test approach that is used to more accurately detect a variety of mutations using small amounts of tissue. Accordingly, NeoGenomics accept sucked fine needle and other minute samples for testing.

In March, NeoGenomics announced that he was the first to offer plasma-based next-generation tests for hematological neoplasms. This test can allow patients to avoid bone marrow biopsy, and allow clinicians to monitor tumor load and detect emerging sub-clones. Neotype ™ plasma-based test using NGS is now available for AML Prognostic, CLL Prognostic, JMML, lymphoma, MDS / CSA, MPN, and a comprehensive, 54-gene profile myeloid disorders.

Similarly, the neotype solid tumors ™ tests are designed to provide accurate and comprehensive coverage of molecular abnormalities "action" specifically found in the tumor tested. screening for cancer solid tumor neotype ™ is available to the brain, breast, cervical, colorectal, endometrial, esophageal, gastrointestinal stromal (GIST), lung, melanoma, ovarian cancer, soft tissue , thyroid, and other solid tumors.

Douglas VanOort, the company's president and CEO, said: "profiling of the tumor is the key to precision medicine, and we look forward to next generation sequencing tools in the hands of our customers physicians. We have worked hard to develop an innovative and unique approach, using multiple technologies, plasma testing, expert interpretation and reporting results, and other tools for effective cancer screening for our health care system and information for doctors and patients. our company is a privilege to provide the most advanced tools available for very personalized cancer treatment a patient. "

Dr. Maher Albitar, Chief Medical Officer and Director of Research and Development of the Company, commented: "These new profiles are designed to provide information that clinicians can use to manage their patients. They provide information on the clinical behavior, prognosis and potential response to drugs and experimental therapies being currently approved clinical trials. Although each profile covers, on average, less than 20 molecular defects in action different, doctors can customize each profile and add additional genes from a list of validated genes. We believe these small targeted gene profiles of the pilot are the most clinically appropriate cancer screening approach given medicines targeted currently available. "


EmoticonEmoticon